Evgen’s results were in line with our expectations. The group remains a good custodian of investor capital, managing a lean but productive operation. With £5.5m of cash on account (Sept. 30/2016), the Company has a strong balance sheet and is funded to complete its current clinical programmes. The group’s two Phase II clinical trials are progressing to plan, with both studies expected to report in H1-2018 (calendar year). Of note, over the period the group secured orphan des
09 Dec 2016
Trial readouts expected in H1-2018
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trial readouts expected in H1-2018
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.31m
- Published:
09 Dec 2016 -
Author:
Vadim Alexandre -
Pages:
16
Evgen’s results were in line with our expectations. The group remains a good custodian of investor capital, managing a lean but productive operation. With £5.5m of cash on account (Sept. 30/2016), the Company has a strong balance sheet and is funded to complete its current clinical programmes. The group’s two Phase II clinical trials are progressing to plan, with both studies expected to report in H1-2018 (calendar year). Of note, over the period the group secured orphan des